Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
- 15 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (14), 3771-3783
- https://doi.org/10.1158/1078-0432.ccr-19-3018
Abstract
Purpose: Although taxane-based therapy is standard treatment for advanced gastric cancer, a majority of patients exhibit intrinsic resistance to taxanes. Here, we aim to identify the molecular basis of taxane resistance in gastric cancer. Experimental Design: We performed a post hoc analysis of the TAX-325 clinical trial and molecular interrogation of gastric cancer cell lines to assess the benefit of docetaxel in diffuse (DIF-GC) versus intestinal (INT-GC) gastric cancer. We assessed drug-induced microtubule stabilization in gastric cancer cells and in biopsies of patients with gastric cancer treated with taxanes. We performed transcriptome analysis in taxane-treated gastric cancer cells and patients to identify molecular drivers of taxane resistance. Results: Patients with DIF-GC did not derive a clinical benefit from taxane treatment suggesting intrinsic taxane resistance. DIF-GC cell lines displayed intrinsic resistance specific to taxanes because of impaired drug-induced microtubule stabilization, in the absence of tubulin mutations or decreased drug accumulation. Using taxane-treated gastric cancer patient biopsies, we demonstrated that absence of drug–target engagement was correlated with clinical taxane resistance. Taxane-sensitive cell lines displayed faster microtubule dynamics at baseline, implicating proteins that regulate cytoskeletal dynamics in intrinsic taxane resistance. Differential gene expression analysis of untreated and docetaxel-treated gastric cancer lines and patient samples identified kinesins to be associated with taxane sensitivity in vitro and in patient samples. Conclusions: Our data reveal that taxane resistance is more prevalent in patients with DIF-GC, support assessment of drug–target engagement as an early read-out of taxane clinical efficacy, and encourage the investigation of kinesins and other microtubule-associated proteins as potentially targetable mediators of taxane resistance in gastric cancer.Keywords
Other Versions
Funding Information
- NIH NCATS (UL1TR002384)
- NIH (T32 CA062948)
- NIH (T32CA203702)
- NIH NCI (R01 CA179100)
- NIH NCI (R01 CA228512)
- NIH NCI (R21 CA216800)
This publication has 58 references indexed in Scilit:
- EB1-Recruited Microtubule +TIP Complexes Coordinate Protrusion Dynamics during 3D Epithelial RemodelingCurrent Biology, 2012
- plusTipTracker: Quantitative image analysis software for the measurement of microtubule dynamicsJournal of Structural Biology, 2011
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to ChemotherapyGastroenterology, 2011
- A Complex of Kif18b and MCAK Promotes Microtubule Depolymerization and Is Negatively Regulated by Aurora KinasesCurrent Biology, 2011
- Molecular Classification of Gastric Cancer: A New ParadigmClinical Cancer Research, 2011
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsAnnals of Oncology, 2011
- Farnesyl transferase expression determines clinical response to the docetaxel‐lonafarnib combination in patients with advanced malignanciesCancer, 2011
- Kinesin superfamily motor proteins and intracellular transportNature Reviews Molecular Cell Biology, 2009
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Global cancer statistics in the year 2000The Lancet Oncology, 2001